A compound of formula I wherein: R 1 is selected from pyrrolidin-1-yl, piperidin-1-yl, azetidin-1-yl, 5-azaspiro[2.3]hexan-5-yl, azepan-1-yl, 3-azabicyclo[3.1.0.]hexan-3-yl, cyclohexyl, cyclohexen-1-yl, cyclohexylamino and cyclopentylamino, wherein each R 1 is substituted with -CO 2 H or -CH 2 CO 2 H and optionally further substituted by a group selected from C 1-3 alkyl, OH, -CH 2 OMe, -CF 3 and -F, and wherein two different carbons in said pyrrolidin-1-yl, piperidin-1-yl, azetidin-1-yl or azepan-1-yl may optionally be joined by a C 1-3 alkylene bridge; or R 1 is -N(R 6)(CH 2) 2-3 CO 2 H; R 2 and R 3 are independently selected from H, C 1-6 alkyl, halogen, -CN and -CF 3, provided that at least one of R 2 or R 3 is H; R 4 is selected from -C N(R 6)(R 7), -C R 8 and -CH(R 6)R 9; R 5 is selected from H, C 1-4 alkyl, halogen, -CF 3, -OC 1-4 alkyl, -OCF 3 and -CN; R 6 is H, -CH 3 or CH 2 CH 3; R 7 is selected from -CH 3, -CH 2 CH 3, -(CH 2) 2-3 OCH 3, -(CH 2) 2 N(CH 3) 2, C 1-3 alkyl, -(CH 2) 1-2 CN,-(CH 2) 2-3 OH, -CH 2 C NHCH 3, -CH 2 C N(CH 3) 2, -CH 2 -tetrahydrofuranyl, -CH 2 -1-methylpyrrazol-3-yl, -CH 2 -1-methylpyrrazol-4-yl, -CH 2 -1-methylpyrrazol-5-yl, -CH 2 -imidazol-2-yl and -(CH 2) 0-1 cyclohexyl; R 8 is selected from azepan-1-yl, azetidin-1-yl, 1,1-dioxothiomorpholin-4-yl, morpholin-4-yl, piperidin-1-yl, piperazin-1-yl, pyrrolidin-1-yl, [1,4]oxazepan-4-yl, 5, 6, 7, 8-tetrahydro[1,2,4]triazolo[1,5-a]pyrazin-7-yl and 5,6,7,8-[1,2,4]triazolo[4,3-a]pyrazine-7-yl and is optionally substituted with one to three groups independently selected from C 1-3 alkyl, -CH 2 OH, -OCH 3, -N(CH 3) 2, -OH, oxo, -CN and halogen; R 9 is a heterocyclyl selected from morpholin-4-yl, 1,1-dioxothiomorpholin-4-yl, pyrrolidin-1-yl, piperidin-1-yl, octahydropyrrolo[1,2-a]pyrazin-2-yl and piperazin-1-yl, wherein said heterocyclyl is optionally substituted with one to three groups independently selected from C 1-3 alkyl, -CH 2 OH, -CH 2 OCH 3, halogen, -CN, oxo, -OH, -SO 2 C 1-6 alkyl, -SO 2 N(C 1-6 alkyl) 2, -C NH 2, -C NHCH 3, -C N(CH 3) 2, C C 1-6 alkyl, -C C 3-6 cycloalkyl, and -C tetrahydrofuran-3-yl; or R 9 is -N(R 6)(R 10); R 10 is tetrahydropyran-4-ylmethyl, C 3-6 cycloalkyl, C 3-6 cycloalkylmethyl, 1,1-dioxotetrahydrothiophen-3-yl, -CH 2 C(CH 3) 2 OH, -CH 2 C(CH 3) 2 CH 2 OH, -C(CH 3) 2 CH 2 OH,-CH 2 (CH 2) 1-2 OCH 3 or -CH 2 CH 2 CO 2 H; and n is 1 or 2; or a salt thereof. R 1 is selected from pyrrolidin-1-yl, piperidin-1-yl, azetidin-1-yl, 5-azaspiro[2.3]hexan-5-yl, azepan-1-yl, 3-azabicyclo[3.1.0.]hexan-3-yl, cyclohexyl, cyclohexen-1-yl, cyclohexylamino and cyclopentylamino, wherein each R 1 is substituted with -CO 2 H or -CH 2 CO 2 H and optionally further substituted by a group selected from C 1-3 alkyl, OH, -CH 2 OMe, -CF 3 and -F, and wherein two different carbons in said pyrrolidin-1-yl, piperidin-1-yl, azetidin-1-yl or azepan-1-yl may optionally be joined by a C 1-3 alkylene bridge; or R 1 is -N(R 6)(CH 2) 2-3 CO 2 H; R 2 and R 3 are independently selected from H, C 1-6 alkyl, halogen, -CN and -CF 3, provided that at least one of R 2 or R 3 is H; R 4 is selected from -C N(R 6)(R 7), -C R 8 and -CH(R 6)R 9; R 5 is selected from H, C 1-4 alkyl, halogen, -CF 3, -OC 1-4 alkyl, -OCF 3 and -CN; R 6 is H, -CH 3 or CH 2 CH 3; R 7 is selected from -CH 3, -CH 2 CH 3, -(CH 2) 2-3 OCH 3, -(CH 2) 2 N(CH 3) 2, C 1-3 alkyl, -(CH 2) 1-2 CN,-(CH 2) 2-3 OH, -CH 2 C NHCH 3, -CH 2 C N(CH 3) 2, -CH 2 -tetrahydrofuranyl, -CH 2 -1-methylpyrrazol-3-yl, -CH 2 -1-methylpyrrazol-4-yl, -CH 2 -1-methylpyrrazol-5-yl, -CH 2 -imidazol-2-yl and -(CH 2) 0-1 cyclohexyl; R 8 is selected from azepan-1-yl, azetidin-1-yl, 1,1-dioxothiomorpholin-4-yl, morpholin-4-yl, piperidin-1-yl, piperazin-1-yl, pyrrolidin-1-yl, [1,4]oxazepan-4-yl, 5, 6, 7, 8-tetrahydro[1,2,4]triazolo[1,5-a]pyrazin-7-yl and 5,6,7,8-[1,2,4]triazolo[4,3-a]pyrazine-7-yl and is optionally substituted with one to three groups independently selected from C 1-3 alkyl, -CH 2 OH, -OCH 3, -N(CH 3) 2, -OH, oxo, -CN and halogen; R 9 is a heterocyclyl selected from morpholin-4-yl, 1,1-dioxothiomorpholin-4-yl, pyrrolidin-1-yl, piperidin-1-yl, octahydropyrrolo[1,2-a]pyrazin-2-yl and piperazin-1-yl, wherein said heterocyclyl is optionally substituted with one to three groups independently selected from C 1-3 alkyl, -CH 2 OH, -CH 2 OCH 3, halogen, -CN, oxo, -OH, -SO 2 C 1-6 alkyl, -SO 2 N(C 1-6 alkyl) 2, -C NH 2, -C NHCH 3, -C N(CH 3) 2, C C 1-6 alkyl, -C C 3-6 cycloalkyl, and -C tetrahydrofuran-3-yl; or R 9 is -N(R 6)(R 10); R 10 is tetrahydropyran-4-ylmethyl, C 3-6 cycloalkyl, C 3-6 cycloalkylmethyl, 1,1-dioxotetrahydrothiophen-3-yl, -CH 2 C(CH 3) 2 OH, -CH 2 C(CH 3) 2 CH 2 OH, -C(CH 3) 2 CH 2 OH,-CH 2 (CH 2) 1-2 OCH 3 or -CH 2 CH 2 CO 2 H; and n is 1 or 2; or a salt thereof.